Tg Therapeutics (TGTX) EBIT (2016 - 2025)
Historic EBIT for Tg Therapeutics (TGTX) over the last 10 years, with Q3 2025 value amounting to $29.4 million.
- Tg Therapeutics' EBIT rose 13616.7% to $29.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $102.8 million, marking a year-over-year increase of 2045227.72%. This contributed to the annual value of $41.9 million for FY2024, which is 10321.33% up from last year.
- Per Tg Therapeutics' latest filing, its EBIT stood at $29.4 million for Q3 2025, which was up 13616.7% from $34.8 million recorded in Q2 2025.
- Over the past 5 years, Tg Therapeutics' EBIT peaked at $114.8 million during Q3 2023, and registered a low of -$92.9 million during Q4 2021.
- In the last 5 years, Tg Therapeutics' EBIT had a median value of -$35.0 million in 2022 and averaged -$22.5 million.
- In the last 5 years, Tg Therapeutics' EBIT soared by 42830.13% in 2023 and then crashed by 8916.75% in 2024.
- Over the past 5 years, Tg Therapeutics' EBIT (Quarter) stood at -$92.9 million in 2021, then grew by 16.58% to -$77.5 million in 2022, then skyrocketed by 83.9% to -$12.5 million in 2023, then soared by 339.88% to $29.9 million in 2024, then dropped by 1.95% to $29.4 million in 2025.
- Its EBIT stands at $29.4 million for Q3 2025, versus $34.8 million for Q2 2025 and $8.6 million for Q1 2025.